| Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) S Fukuoka, H Hara, N Takahashi, T Kojima, A Kawazoe, M Asayama, ... Journal of Clinical Oncology 38 (18), 2053-2061, 2020 | 693 | 2020 |
| Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial K Yoh, T Seto, M Satouchi, M Nishio, N Yamamoto, H Murakami, ... The Lancet Respiratory Medicine 5 (1), 42-50, 2017 | 327 | 2017 |
| Prognostic significance of complications after curative surgery for gastric cancer T Kubota, N Hiki, T Sano, S Nomura, S Nunobe, K Kumagai, S Aikou, ... Annals of surgical oncology 21, 891-898, 2014 | 256 | 2014 |
| Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial A Kawazoe, S Fukuoka, Y Nakamura, Y Kuboki, M Wakabayashi, ... The Lancet Oncology 21 (8), 1057-1065, 2020 | 228 | 2020 |
| Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial Y Nakamura, W Okamoto, T Kato, T Esaki, K Kato, Y Komatsu, S Yuki, ... Nature medicine 27 (11), 1899-1903, 2021 | 173 | 2021 |
| TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm … Y Kuboki, T Nishina, E Shinozaki, K Yamazaki, K Shitara, W Okamoto, ... The Lancet Oncology 18 (9), 1172-1181, 2017 | 160 | 2017 |
| Influence of ground glass opacity and the corresponding pathological findings on survival in patients with clinical stage I non–small cell lung cancer K Aokage, T Miyoshi, G Ishii, M Kusumoto, S Nomura, S Katsumata, ... Journal of Thoracic Oncology 13 (4), 533-542, 2018 | 144 | 2018 |
| Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial K Nakachi, M Ikeda, M Konishi, S Nomura, H Katayama, T Kataoka, ... The Lancet 401 (10372), 195-203, 2023 | 126 | 2023 |
| Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study T Hishida, S Nomura, M Yano, H Asamura, M Yamashita, Y Ohde, ... European Journal of Cardio-Thoracic Surgery 49 (3), 835-841, 2016 | 119 | 2016 |
| Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205) K Shitara, T Doi, O Nagano, CK Imamura, T Ozeki, Y Ishii, K Tsuchihashi, ... Gastric Cancer 20, 341-349, 2017 | 105 | 2017 |
| Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long‐term survivors of aggressive adult T‐cell leukaemia‐lymphoma (JCOG0902A) T Fukushima, S Nomura, M Shimoyama, T Shibata, Y Imaizumi, ... British journal of haematology 166 (5), 739-748, 2014 | 103 | 2014 |
| Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma K Hatogai, S Kitano, S Fujii, T Kojima, H Daiko, S Nomura, T Yoshino, ... Oncotarget 7 (30), 47252, 2016 | 94 | 2016 |
| Effect of novel bright image enhanced endoscopy using blue laser imaging (BLI) K Kaneko, Y Oono, T Yano, H Ikematsu, T Odagaki, Y Yoda, A Yagishita, ... Endoscopy international open 2 (04), E212-E219, 2014 | 93 | 2014 |
| Risk factor analysis and prevention of postoperative pancreatic fistula after distal pancreatectomy with stapler use M Sugimoto, N Gotohda, Y Kato, S Takahashi, T Kinoshita, H Shibasaki, ... Journal of Hepato‐Biliary‐Pancreatic Sciences 20 (5), 538-544, 2013 | 91 | 2013 |
| Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). S Fukuoka, H Hara, N Takahashi, T Kojima, A Kawazoe, M Asayama, ... Journal of Clinical Oncology 37 (15_suppl), 2522-2522, 2019 | 81 | 2019 |
| Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 … C Morizane, N Machida, Y Honma, T Okusaka, N Boku, K Kato, S Nomura, ... JAMA oncology 8 (10), 1447-1455, 2022 | 78 | 2022 |
| Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer: a framework for developing an objective pathological diagnostic system using the … M Kojima, H Shimazaki, K Iwaya, M Kage, J Akiba, Y Ohkura, S Horiguchi, ... Journal of Clinical Pathology 66 (7), 551-558, 2013 | 77 | 2013 |
| Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial) A Kawazoe, Y Kuboki, E Shinozaki, H Hara, T Nishina, Y Komatsu, S Yuki, ... Clinical Cancer Research 26 (22), 5887-5894, 2020 | 73 | 2020 |
| Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer … E Shinozaki, T Yoshino, K Yamazaki, K Muro, K Yamaguchi, T Nishina, ... British journal of cancer 117 (10), 1450-1458, 2017 | 73 | 2017 |
| A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201) H Bando, T Doi, K Muro, H Yasui, T Nishina, K Yamaguchi, S Takahashi, ... European Journal of Cancer 62, 46-53, 2016 | 66 | 2016 |
